本文言語 | English |
---|---|
ページ(範囲) | 523-524 |
ページ数 | 2 |
ジャーナル | European Journal of Cancer |
巻 | 157 |
DOI | |
出版ステータス | Published - 11月 2021 |
ASJC Scopus subject areas
- 腫瘍学
- 癌研究
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: European Journal of Cancer, Vol. 157, 11.2021, p. 523-524.
研究成果 › 査読
}
TY - JOUR
T1 - Response to letter re
T2 - The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression
AU - Ochi, Nobuaki
AU - Ichihara, Eiki
AU - Takigawa, Nagio
AU - Harada, Daijiro
AU - Inoue, Koji
AU - Shibayama, Takuo
AU - Hosokawa, Shinobu
AU - Kishino, Daizo
AU - Harita, Shingo
AU - Oda, Naohiro
AU - Hara, Naofumi
AU - Hotta, Katsuyuki
AU - Maeda, Yoshinobu
AU - Kiura, Katsuyuki
N1 - Funding Information: EI received honoraria from Boehringer Ingelheim and additional research funding from MSD. NT received honoraria and research funds from Eli Lilly Japan, AstraZeneca, Daiichi-Sankyo, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer, Boehringer-Ingelheim, and Ono Pharmaceutical. TN received honoraria from MSD, Bristol-Myers Squibb and Eisai. TN received research funds from Kyowa Hakko Kirin, Nippon Kayaku, Takeda Pharmaceutical and Astellas Pharma. DH received research funds from Eli Lilly, MSD, Chugai, Pfizer, BMS, AstraZeneca, Novartis, Kissei and Takeda, honoraria from MSD, ONO pharmaceutical, BMS, Kyowa Hakko Kirin, AstraZeneca, Boehringer Ingelheim and Lilly. SH received honoraria from Bristol–Myers Squibb and MSD. TS received research funding from ONO pharmaceutical and Shionogi pharmaceutical. KH received honoraria from Taiho Pharmaceutical and Chugai Pharmaceutical. KH received additional research funding from MSD and Chugai Pharmaceutical. YM received honoraria from Chugai Pharmaceutical and Bristol–Myers Squibb. KK received honoraria from Chugai Pharmaceuticals.
PY - 2021/11
Y1 - 2021/11
UR - http://www.scopus.com/inward/record.url?scp=85114942163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114942163&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2021.07.044
DO - 10.1016/j.ejca.2021.07.044
M3 - Letter
C2 - 34479780
AN - SCOPUS:85114942163
SN - 0959-8049
VL - 157
SP - 523
EP - 524
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -